Lyell Immunopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lyell Immunopharma, Inc. on June 9, 2025. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its authorized size from seven to eight directors.
- New Appointment: Mark Bachleda, Pharm.D., M.B.A., was appointed as a Class I director. His term will expire at the 2028 annual meeting of stockholders.
- Compensation Structure: Dr. Bachleda will receive an annual cash retainer, an initial equity grant, and annual equity grants pursuant to the Company's Non-Employee Director Compensation Policy.
- Stock Split Adjustment: Equity grant amounts are adjusted for a 1-for-20 reverse stock split that became effective on May 30, 2025.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Bachleda.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, or specific risk factors. The document is limited to the disclosure of the director appointment and associated compensation arrangements.
Key Facts for Investor Verification
- Verify the impact of the 1-for-20 reverse stock split (effective May 30, 2025) on existing share counts and equity valuations.
- Review the specific terms of the Non-Employee Director Compensation Policy (Exhibit 10.1 to the August 7, 2024 Form 10-Q) to understand the exact cash and equity compensation for Dr. Bachleda.
- Confirm the composition of the Board following the increase to eight directors and the specific committee assignments, if any, for the new appointee.